Responses
Poster
IGCS20_1398
372 Safety and activity of the anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer
Compose a Response to This Article
Other responses
No responses have been published for this article.